Protein dysregulation company Prothena Corp. plc (NASDAQ:PRTA) named SVP and Head of Clinical Development Chad Swanson chief development officer. Swanson, a neuropharmacologist, joined Prothena in 2023 from Eisai Co. Ltd. (Tokyo:4523), where he was executive director of clinical research in the Alzheimer’s disease brain health group.
Prothena also announced that it’s looking for a new CMO following the departure of Hideki Garren, who is leaving to lead the neurology division at Roche (SIX:ROG; OTCQX:RHHBY). ...